UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of November 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 17 November 2026, London UK
Nelkarmi
(neladalkib) approved in the US for
previously-treated advanced ALK-positive non-small cell lung
cancer
●
Approval
based on phase I/II ALKOVE-1 trial demonstrating clinically
meaningful and durable responses in pretreated
patients
●
Next-generation
ALK inhibitor designed to help address resistance, disease in the
brain and tolerability challenges
●
GSK’s second approval in lung cancer this
year[1]
GSK plc (LSE/NYSE: GSK) today
announced the US Food and Drug Administration (FDA) has granted
accelerated approval to Nelkarmi (neladalkib) for the treatment of adults with
locally advanced or metastatic anaplastic lymphoma kinase
(ALK)-positive non-small cell lung cancer (NSCLC) who have
previously received the following therapy in the unresectable
locally advanced or metastatic setting: one prior ALK tyrosine
kinase inhibitor (TKI) consisting of alectinib, or two or more
prior ALK TKIs and platinum-based chemotherapy.[2]
This approval comes ahead of the original FDA target action date of
27 November 2026 and follows the FDA's Breakthrough Therapy and
Orphan Drug designations.[3]
Tony Wood, Chief Scientific Officer, GSK said: “Nelkarmi is our second new medicine approved in lung cancer
this year. It was designed to help address key challenges of
ALK-positive non-small cell lung cancer through its broad coverage
of ALK resistance mutations, ability to cross the blood-brain
barrier and high target selectivity. ALK-positive patients are
often younger and can remain on treatment for years, making
effective and tolerable new treatment options especially important,
and we are pleased to bring this innovation to patients in the
US.”
The approval is based on results from the phase I/II ALKOVE-1
trial. For patients previously treated with alectinib as their only
prior ALK TKI, the confirmed overall response rate (ORR) was 49%
(33/67; 95% CI: 37%, 62%), with a duration of response (DOR) as
assessed by blinded independent central review (BICR) of 6 or more
months in 76% of responders and 12 or more months in 52% of
responders. For patients with two or more prior ALK TKIs and
chemotherapy, the ORR was 32% (50/155; 95% CI: 24%, 40%), with DOR
of 6 or more months in 69% of responders and 12 or more months in
51% of responders.2
Among patients with measurable central nervous system (CNS)
metastases at baseline, intracranial ORR was 55% (11/20; 95% CI:
32% 77%) (including 25% complete responses) in those previously
treated with alectinib as their only prior ALK TKI, and 26% (14/53;
95% CI: 15%, 40%) (including 11% complete responses) in those who
had received two or more prior ALK TKIs and
chemotherapy.2
The most common (≥20%) adverse reactions were hepatotoxicity,
musculoskeletal pain, constipation, dysgeusia, peripheral
neuropathy, edema, and fatigue. Permanent discontinuation of
Nelkarmi
due to adverse reactions occurred in
5% of patients. The most frequent adverse reaction that led to
permanent discontinuation was hepatotoxicity.2
Alice Shaw, MD, PhD, an ALKOVE-1 trial investigator, Chair of the
Department of Medical Oncology and Chief of Strategic Partnerships
at Dana-Farber Cancer Institute, said: “Patients with ALK-positive lung cancer are
often treated with multiple targeted therapies over many years.
Advances in treatment have brought us closer to the goal of
managing ALK-positive lung cancer as a chronic condition, but
balancing disease control and long-term tolerability remains a
significant challenge. The approval of neladalkib provides an
important new treatment option for
patients.”
Kirk Smith, President, ALK Positive, said: “For people living with ALK-positive lung
cancer, one of the hardest moments is learning that a treatment
that had been working is no longer controlling the disease. As
patients move through multiple therapies over the course of their
disease, they need options that balance durable disease control
with the ability to tolerate and remain on treatment and maintain
quality of life. Today’s approval represents important
progress for our community.”
Nelkarmi, part of the portfolio
from the recent acquisition of Nuvalent, Inc, is also being
evaluated in ALKAZAR, an ongoing phase III trial in TKI-naïve
ALK-positive NSCLC, and in other solid tumours.
About Nelkarmi (neladalkib)
Nelkarmi is an ALK-selective
tyrosine kinase inhibitor (TKI) approved for the treatment of
adults with locally advanced or metastatic anaplastic lymphoma
kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have
previously received the following therapy in the unresectable
locally advanced or metastatic setting: one prior ALK tyrosine
kinase inhibitor (TKI) consisting of alectinib, or two or more
prior ALK TKIs and platinum-based
chemotherapy.
It was designed to help address treatment resistance and disease
that has spread to the brain, key challenges in ALK-positive NSCLC
and other cancers.
The US Prescribing information will be available
here.
About the ALKOVE-1 trial
ALKOVE-1 (NCT05384626) is a global single-arm phase I/II trial
evaluating neladalkib in patients with advanced ALK-positive NSCLC
and other ALK-positive solid tumours. The trial enrolled 700
patients with ALK-positive solid tumours across the phase I and
phase II portions. The primary efficacy analysis supporting the FDA
approval included 222 patients with previously treated ALK-positive
NSCLC. The major efficacy outcome measures were confirmed overall
response rate (ORR) and duration of response (DOR) as assessed by
blinded independent central review.
About NSCLC
NSCLC is the most common form of lung cancer and is often
characterised by specific genetic alterations, such as those in
ALK, ROS1 or HER2. It can often metastasise (i.e. spread) to the
central nervous system. It primarily affects working-age
individuals. Current treatments may have efficacy and/or
tolerability limitations that leave unmet need for
patients.
About GSK in oncology
GSK is focused on developing differentiated medicines for cancers
where patients continue to face poor outcomes, treatment
resistance, limited options or significant treatment burden. We
focus where advances in science and technology offer the greatest
opportunity to improve outcomes across haematological, lung,
gastrointestinal, genitourinary and gynaecological cancers. Across
multiple modalities, including targeted small molecules,
antibody-drug conjugates (ADCs) and immunotherapies, GSK applies
deep expertise in cancer biology and immune system science to
develop differentiated medicines designed to deliver durable
responses, overcome resistance and reduce treatment
burden.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at www.gsk.com.
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Sarah
Clements
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
Alison
Hunt
|
+1 540
742 3391
|
(Washington
DC)
|
|
|
|
|
|
|
|
|
|
|
|
Investor
Relations:
|
James
Dodwell
|
+44 (0)
7881 269066
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Joanna
Tuplin
|
+44 (0)
7788 351650
|
(London)
|
|
|
Sam
Piper
|
+44 (0)
7824 525779
|
(London)
|
|
|
Dan
Smith
|
+44 (0)
7823 523885
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Frannie
DeFranco
|
+1 215
751 3126
|
(Philadelphia)
|
|
|
|
|
|
|
|
|
|
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the “Risk
Factors” section in GSK’s Annual Report on Form 20-F
for 2025, and GSK’s Q3 Results for 2026.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
References
[1] GSK press release, Jideytro
(zidesamtinib) approved in the US for previously treated
ROS1-positive non-small cell lung cancer, July
2026
[2] Nelkarmi (neladalkib) US
Prescribing Information. November 2026.
[3] Nuvalent
Announces Submission of New Drug Application to FDA for Neladalkib
in TKI Pre-treated Advanced ALK-positive NSCLC - Apr 7,
2026
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: November
18, 2026
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|